After extensive exploration and research, VCBeat’s VB100 has ultimately selected Indonesia as the first destination for its series of initiatives supporting the overseas expansion of medical device companies. As the world’s fourth-most populous country, Indonesia is home to nearly 280 million people, accounting for more than 40% of Southeast Asia’s total population. Its economy maintains steady growth, ranking first in Southeast Asia. However, the domestic self-sufficiency rate for medical equipment and pharmaceuticals remains low, with 90% reliant on imports. From high-end equipment such as CT scanners and MRI machines to low-value consumables like disposable infusion sets and medical dressings, Indonesia exhibits substantial import demand. This undoubtedly presents an optimal window for Chinese medical enterprises to enter the Indonesian market.

However, expanding into the Indonesian market is by no means an easy endeavor. The complex local market environment, diverse cultural backgrounds, and regulatory frameworks—particularly regarding registration and approval processes and hospital access policies in the healthcare sector—have undoubtedly left Chinese companies feeling shrouded in uncertainty.

Scan the QR Code to Register

To this end,VCBeatVB100In partnership with Legend Capital, the 2024 VBEF Medical Device Global Expansion Online Salon—Let’s Go! Indonesia was held at 15:00 on February 28, 2024. Intended invitees includeChina-Indonesia Chamber of Commerce, Legend Capital, Haihe BiotechnologyThis sharing session aims to help Chinese enterprises understand the macro-environment of the Indonesian market, the current status and opportunities in the medical device industry, strategies for overseas expansion, and an interpretation of the medical device registration process, thereby enabling them to cut through the uncertainty and accelerate their entry into Indonesia and the broader Southeast Asian market.

Final agenda subject to change on the day of the conference

Scan the QR Code to Register

VB100 is a brand under Eggshell Technology, dedicated to servingGovernment, Industrial Parks, Large Corporations, Innovative EnterprisesAs a business unit, we connect governments with innovative enterprises, and large corporations with innovative startups, through a diverse range of activities including summits, competitions, forums, roadshows, seminars, salons, closed-door meetings, case study collections, and partner selection processes. These efforts foster global industrial resource collaboration and drive industrial upgrading. To better showcase China’s high-quality medical and healthcare products to the world, assist medical enterprises in actively expanding into Asian and international markets, and build international brand presence, VB100 has launched the “Medical Device Global Expansion (Indonesia)” series of initiatives. This program provides in-depth support for companies entering the Indonesian market, including but not limited to facilitating deep connections between Chinese enterprises and local Indonesian associations, the Medical Device Supervision and Administration Agency, and other relevant institutions; identifying local distributors and agency partners; and enhancing companies’ influence in Indonesia. The aim is to deliver deeper, more valuable services to support enterprises in their global expansion.

Legend Capital was established in April 2001 and is a leading professional investment firm in China, specializing in early-stage venture capital and growth-stage private equity. Over the past two decades, Legend has adhered to international best practices, successfully managing multiple funds through their full life cycles and delivering outstanding, sustainable performance. To date, it has invested in more than 600 companies, with 110 achieving exits through initial public offerings (IPOs) on various global capital markets and nearly 100 exiting via mergers and acquisitions. Staying true to its original mission, Legend Capital fosters corporate innovation and growth, as well as industrial progress and social development, by providing both capital and managerial support. While delivering strong financial returns, the firm actively fulfills its social responsibilities, striving for sustainable and high-quality development.

The Indonesia-China Chamber of Commerce (INACHAM) is the official Indonesian chamber of commerce in China. The chamber’s primary objectives are to promote investment between China and Indonesia; to facilitate, support, and expand bilateral trade; to accelerate and boost tourism exchanges between the two countries; and to serve as a bridge for enhancing people-to-people ties and fostering friendly exchanges between the two nations.

Haihe Biologics is a platform-based company specializing in providing full-lifecycle product services to research institutions, R&D and manufacturing enterprises, and regulatory authorities in the medical device and pharmaceutical sectors. It holds a prominent industry position in the biopharmaceutical CRO field. The company offers strategic planning for global market access, tailors commercialization pathways for clients, and helps them complete product marketing authorization applications in the fastest and most cost-effective manner.